New patent for SPI-339, Potential ADHD Drug
Spectrum Pharmaceuticals got a patent for a potential ADHD drug SPI-339. Filed under
Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives.
SPI-339 is an orally available small molecule drug that has potential applications for the treatment of attention disorders, memory acquisition and other cognitive functions. Potential applications of SPI-339 include treatment of children and adults with ADHD. Although the precise mechanism of action of SPI-339 is not known, it is known to be different from that of the stimulants that are commonly used to treat ADHD.
Apparently they’ll be out licensing the drug for further development and marketing
Innovation is a good thing, hopefully it becomes s a useful drug for ADDers.
